The Next Stage of Buprenorphine Care for Opioid Use Disorder
The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Abstract
Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, while our GBOT model includes psychoeducation components with varying degrees of rigor, psychotherapeutic counseling is not necessary for successful outcomes in B/N treatment.21”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [21]
Citations
Cites
Extensional versus intuitive reasoning: The conjunction fallacy in probability judgment.
Tversky, A., & Kahneman, D. (1983) · Psychological Review · doi:10.1037/0033-295x.90.4.293 · Cited by 3,991
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076 · cited 1×
“Buprenorphine, the most commonly used evidencebased treatment of OUD (73, 74) in the United States, is associated with reduced mortality (75, 76).”
BackgroundMedication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Tolerating Uncertainty — The Next Medical Revolution?
Simpkin, A. L., & Schwartzstein, R. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606402 · Cited by 521
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · cited 1×
“Early cessation of buprenorphine treatment can have catastrophic effects, including death (21, 64).”
BackgroundDrugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011-2016.
Hedegaard, H. B., Bastian, B. A., Trinidad, J. P., Spencer, M. R. T., & Warner, M. (2018) · PubMed · Cited by 394
Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000193 · Cited by 333 · cited 1×
“A systematic review of psychosocial counseling provided with MAT found that “support for the efficacy of delivering concurrent psychosocial interventions was less robust for buprenorphine” (45).”
Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010) · BMJ · doi:10.1136/bmj.c5475 · Cited by 307 · cited 1×
“A 2010 analysis found no reduction in mortality until 20 weeks of treatment; opioid substitution treatment for 12 months or longer was needed to achieve a chance greater than 85% of reducing overall mortality (66).”
Background
Research works printed but not linked: 5
- Sansone RA, 2015, Innov Clin Neurosci, 12, 32
- Warner M, 2016, Natl Vital Stat Rep, 65, 1
- Knopf A, 2017, Alcoholism & Drug Abuse Weekly, 29, 3
- Gabrielson R, 2016, The New York Times, MM34
- Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
Cited by
Defining Low-threshold Buprenorphine Treatment
Jakubowski, A., & Fox, A. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000555 · Cited by 203
Krawczyk, N., Williams, A. R., Saloner, B. K., & Cerdá, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108329 · Cited by 153
Brown, E., Schutze, M., Taylor, A., Jorgenson, D., McGuire, C. A., Brown, A., Middleton, A., Woodcock, C., LaPres, M., Cohn, L. M., et al. (2021) · JAMA · doi:10.1001/jama.2021.7374 · Cited by 124
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada
Piske, M., Zhou, H., Min, J. E., Hongdilokkul, N., Pearce, L. A., Homayra, F., Socias, M. E., McGowan, G., & Nosyk, B. (2020) · Addiction · doi:10.1111/add.14947 · Cited by 114
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D. M., & Bagley, S. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06904-4 · Cited by 114
Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid
Samples, H., Williams, A. R., Crystal, S., & Olfson, M. (2020) · Health Affairs · doi:10.1377/hlthaff.2019.01085 · Cited by 106
Beetham, T., Saloner, B., Wakeman, S. E., Gaye, M., & Barnett, M. L. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3457 · Cited by 105
Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder
Krans, E. E., Kim, J. Y., James, A. E., Kelley, D., & Jarlenski, M. P. (2019) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003231 · Cited by 99
Unmet substance use disorder treatment need among reproductive age women
Martin, C. E., Scialli, A. C., & Terplan, M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107679 · Cited by 98
Hood, J. E., Banta‐Green, C. J., Duchin, J. S., Breuner, J., Dell, W., Finegood, B., Glick, S. N., Hamblin, M., Holcomb, S., Mosse, D., et al. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1635557 · Cited by 83
Appointment wait-times and arrival for patients at a low-barrier access addiction clinic
Roy, P. J., Choi, S., Bernstein, E., & Walley, A. Y. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108011 · Cited by 66
Krawczyk, N., Garrett, B. A., Ahmad, N. J., Patel, E., Solomon, K. T., Stuart, E. A., & Saloner, B. K. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108512 · Cited by 54
Strayer, R. J., Hawk, K. F., Hayes, B. D., Herring, A. A., Ketcham, E. M., LaPietra, A. M., Lynch, J. J., Motov, S. M., Repanshek, Z. D., Weiner, S. G., et al. (2020) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.12.034 · Cited by 50
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic
Pytell, J. D., & Rastegar, D. A. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108155 · Cited by 49
Anderson, J., Martin, S. A., Gadomski, A., Krupa, N. L., Mullin, D. J., Cahill, A., & Jenkins, P. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1931633 · Cited by 48
Self-citationAwareness, perception and utilization of a mobile health clinic by people who use drugs
Grieb, S. M. D., Harris, R., Rosecrans, A. M., Zook, K. J. C., Sherman, S. G., Greenbaum, A. H., Lucas, G. M., & Page, K. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2021.2022188 · Cited by 47
Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs
Thakarar, K., Nenninger, K., & Agmas, W. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.06.013 · Cited by 47
Manhapra, A., Stefanovics, E. A., & Rosenheck, R. A. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1640831 · Cited by 42
Edwards, F. J., Wicelinski, R., Gallagher, N., McKinzie, A., White, R. D., & Domingos, A. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.08.420 · Cited by 42
Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality
Gertner, A. K., Robertson, A. G., Powell, B. J., Jones, H. E., Silberman, P., & Domino, M. E. (2020) · Health Affairs · doi:10.1377/hlthaff.2019.01559 · Cited by 40
Snell‐Rood, C., Pollini, R. A., & Willging, C. E. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000312 · Cited by 40
Xu, K. Y., Mintz, C. M., Presnall, N. J., Bierut, L. J., & Grucza, R. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11363 · Cited by 40
Harm Reduction in Health Care Settings
Chan, C. A., Canver, B., McNeil, R., & Sue, K. L. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.09.002 · Cited by 39
Health Professionals’ Attitudes toward Medications for Opioid use Disorder
Brown, A. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1975872 · Cited by 38
ACMT Position Statement: Buprenorphine Administration in the Emergency Department
Wax, P. M., Stolbach, A. I., Schwarz, E. S., Warrick, B. J., Wiegand, T. J., & Nelson, L. S. (2019) · Journal of Medical Toxicology · doi:10.1007/s13181-019-00712-3 · Cited by 37
Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine
Neale, K., Weimer, M. B., Davis, M. P., Jones, K. F., Kullgren, J. G., Kale, S. S., Childers, J. W., Broglio, K., Merlin, J. S., Peck, S., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0399 · Cited by 34
Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention
Williams, A. R., Mauro, C., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. M. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220456 · Cited by 34
Self-citationData 2000 Waiver Training for Medical Students: Lessons Learned from a Medical School Experience
Zerbo, E. A., Traba, C. M., Matthew, P., Chen, S., Holland, B. K., Levounis, P., Nelson, L. S., & Lamba, S. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1692323 · Cited by 33
Hooker, S. A., Sherman, M. D., Lonergan, M. E., Nissly, T. J., & Levy, R. J. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108804 · Cited by 33
Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients
Herscher, M., Fine, M., Navalurkar, R., Hirt, L., & Wang, L. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.003 · Cited by 32
Sokol, R. G., Tammaro, E., Kim, J. Y., & Stopka, T. J. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1906280 · Cited by 31
Snell‐Rood, C., Willging, C. E., Showalter, D., Peters, H., & Pollini, R. A. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1846149 · Cited by 30
Jones, K. F., Ho, J. J., Sager, Z. S., Childers, J. W., & Merlin, J. S. (2021) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909121999783 · Cited by 29
Sousa, J., Raja, P. V., Huskamp, H. A., Mehrotra, A., Busch, A. B., Barnett, M. L., & Uscher‐Pines, L. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001006 · Cited by 28
Revive and Refuse: Capacity, Autonomy, and Refusal of Care After Opioid Overdose
Marshall, K. D., Derse, A. R., Weiner, S. G., & Joseph, J. W. (2023) · The American Journal of Bioethics · doi:10.1080/15265161.2023.2209534 · Cited by 28
Wyse, J. J. B., Morasco, B. J., Dougherty, J., Edwards, B., Kansagara, D. L., Gordon, A. J., Korthuis, P. T., Tuepker, A., Lindner, S., Mackey, K., et al. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108923 · Cited by 27
A mixed methods study of provider factors in buprenorphine treatment retention
Gertner, A. K., Clare, H. M., Powell, B. J., Gilbert, A. R., Jones, H. E., Silberman, P., Shea, C. M., & Domino, M. E. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103715 · Cited by 26
Chang, H., Krawczyk, N., Schneider, K. E., Ferris, L. M., Eisenberg, M. D., Richards, T. M., Lyons, B. C., Jackson, K., Weiner, J. P., & Saloner, B. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.04.016 · Cited by 26
How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis
Hadland, S. E. (2019) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2019.05.008 · Cited by 26
Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care
Ho, J. J., Jones, K. F., Sager, Z. S., Neale, K., Childers, J. W., Loggers, E. T., & Merlin, J. S. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.05.004 · Cited by 25
Lowenstein, M., Abrams, M. P., Crowe, M., Shimamoto, K., Mazzella, S., Botcheos, D., Bertocchi, J., Westfahl, S., Chertok, J., Garcia, K. P., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109915 · Cited by 23
Lowenstein, M., Perrone, J., McFadden, R. B., Xiong, R. A., Meisel, Z. F., O’Donnell, N., Abdel-Rahman, D., Moon, J., Mitra, N., & Delgado, M. K. (2023) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2023.03.033 · Cited by 23
Nurse Practitioners’ Pivotal Role in Ending the Opioid Epidemic
Moore, D. J. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.01.005 · Cited by 23
Jakubowski, A. U., Lu, T. Y., DiRenno, F. A., Jadow, B. M., Giovanniello, A., Nahvi, S., Cunningham, C. O., & Fox, A. D. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108140 · Cited by 22
Thakarar, K., Kohut, M. R., Hutchinson, R. N., Bell, R., Loeb, H. E., Burris, D., & Fairfield, K. M. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00660-2 · Cited by 22
Buprenorphine for Chronic Pain Management: a Narrative Review
Vu, P. D., Bansal, V., Chitneni, A., Robinson, C. L., Viswanath, O., Urits, I., Kaye, A. D., Nguyen, A., Govindaraj, R., Chen, G. H., et al. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01185-4 · Cited by 21
Frost, T., Deutsch, S., Brown, S., Lemien, E., Cunningham, C. O., & Fox, A. D. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1901173 · Cited by 21
Hayes, B. T., Jakubowski, A. U., Fitzsimmons, C., Garcia, B., Ramirez, F., & Fox, A. D. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1908360 · Cited by 20
Krawczyk, N., Mojtabai, R., Stuart, E. A., Fingerhood, M., Agus, D., Lyons, B. C., Weiner, J. P., & Saloner, B. K. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1828440 · Cited by 20
Adams, J. W., Savinkina, A. A., Fox, A. D., Behrends, C. N., Madushani, R. W. M. A., Wang, J., Chatterjee, A., Walley, A. Y., Barocas, J. A., & Linas, B. P. (2022) · Addiction · doi:10.1111/add.15883 · Cited by 19
Retention in Care as a Quality Measure for Opioid use Disorder
Martin, S. A., Chiodo, L. M., & Wilson, A. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1635969 · Cited by 18
Self-citationBuprenorphine-Related Deaths in North Carolina from 2010 to 2018
Bishop-Freeman, S. C., Friederich, L., Feaster, M. S., & Hudson, J. S. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab073 · Cited by 17
Marino, R. T., Perrone, J., Nelson, L. S., Wiegand, T. J., Schwarz, E. S., Wax, P. M., & Stolbach, A. I. (2019) · Journal of Medical Toxicology · doi:10.1007/s13181-019-00728-9 · Cited by 16
Sokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0176-y · Cited by 14
Mattle, A. G., Aladeen, T. S., Blondell, R. D., Capote, H. A., & Rainka, M. M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1405 · Cited by 14
Garneau, H. C., Hurley, B., Fisher, T., Newman, S., Copeland, M., Caton, L., Cheng, H. L., & McGovern, M. P. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108395 · Cited by 14
Williams, A. R., Mauro, C., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. M. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108770 · Cited by 13
Self-citationBuprenorphine Use in Palliative Care
Jones, K. F. (2019) · Journal of Hospice and Palliative Nursing · doi:10.1097/njh.0000000000000598 · Cited by 13
Routes of non-traditional entry into buprenorphine treatment programs
Champagne‐Langabeer, T., Swank, M. W., & Langabeer, J. R. (2020) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-020-0252-z · Cited by 13
Keseg, D. P., Augustine, J. J., Fowler, R. L., Scheppke, K. A., Farcy, D. A., & Pepe, P. E. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.04.017 · Cited by 13
Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes
Oliveira, C., Filipe, R., Meira, J., Sampaio, L., Teixeira, L., Rodrigues, J., Nunes, I. C., & Tavares, J. (2021) · Acta Médica Portuguesa · doi:10.20344/amp.13181 · Cited by 13
Implementing Group Visits for Opioid Use Disorder: A Case Series
Sokol, R., Albanese, M., Albanese, C., Coste, G., Grossman, E., Morrill, D., Roll, D., Sobieszczyk, A., & Schuman-Olivier, Z. (2020) · Substance Abuse · doi:10.1080/08897077.2019.1635958 · Cited by 12
“After starting B/N, patients receive follow-up telephone call 3–5 days later.(12,20,21) When prescriptions are provided: At the end of group Individual visits offered: Yes, 3–4 patients are seen individually for 15-minute appointments after the group (identified ahead of time by the B/Nprovider and as needed) Monitori…”
BackgroundMethodChan, B. L., Cook, R., Levander, X. A., Wiest, K. L., Hoffman, K. A., Pertl, K., Petluri, R., McCarty, D. W., Korthuis, P. T., & Martin, S. A. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209511 · Cited by 12
Self-citationUrine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder
Williams, A. R., Rowe, C. L., Gallagher, R., Aronowitz, S. V., Diamond-Reivich, J., & Bisaga, A. M. (2023) · JAMA Health Forum · doi:10.1001/jamahealthforum.2023.2247 · Cited by 12
Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
Wyse, J. J. B., Eckhardt, A. C., Waller, D. E., Gordon, A. J., Shull, S., Lovejoy, T. I., Mackey, K., & Morasco, B. J. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001292 · Cited by 12
Pro, G. C., Hayes, C. J., Brown, C. C., Goree, J. H., & Zaller, N. D. (2022) · American Journal of Public Health · doi:10.2105/ajph.2021.306503 · Cited by 12
New Challenges and Opportunities for Opioid Agonist Treatment Access and Retention: A Scoping Review
Power, N., Archambault, L., & Perreault, M. (2024) · Journal of Drug Issues · doi:10.1177/00220426241269828 · Cited by 11
A Good Place to Start — Low-Threshold Buprenorphine Initiation
Berk, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2017363 · Cited by 11
Sun, T., Katenka, N., Kogut, S. J., Bratberg, J. P., Rich, J. D., & Buchanan, A. L. (2022) · Pharmacoepidemiology · doi:10.3390/pharma1030010 · Cited by 11
Davoust, M. J., Bazzi, A. R., Blakemore, S., Blodgett, J., Cheng, A., Fielman, S., Magane, K. M., Theisen, J., Saitz, R., Ventura, A. S., et al. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00536-3 · Cited by 10
O’Grady, M. A., Elkington, K. S., Robson, G., Achebe, I. Y., Williams, A. R., COHALL, A. T., Cohall, R. M., Christofferson, M., García, A., Ramsey, K. S., et al. (2024) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-024-00593-y · Cited by 10
Differences in buprenorphine treatment quality across physician provider specialties
Levin, J. S., Landis, R. K., Sorbero, M., Dick, A. W., Saloner, B. K., & Stein, B. D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109510 · Cited by 10
Lépine, B., Debin, M., Dassieu, L., Gimenez, L., Palmaro, A., Ponté, C., Swital, M., Lapeyre‐Mestre, M., Blanchon, T., & Dupouy, J. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108891 · Cited by 9
Sokol, R. G., Suter, S., Pierce, B., Grossman, E., Roland, L., Roll, D. L., & Mintzer, E. (2021) · Healthcare · doi:10.1016/j.hjdsi.2021.100559 · Cited by 9
Sobel, H. G., Warrington, J. S., Francis-Fath, S., Crocker, A. M., & Berger, C. A. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00264-4 · Cited by 8
Faude, S., Delgado, M. K., Perrone, J., McFadden, R. B., Xiong, R. A., O'Donnell, N., Wood, C., Solomon, G., & Lowenstein, M. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.01.009 · Cited by 8
Simpson, M., Ritger, C., Hoppe, J. A., Holland, W. C., Morris, M. A., Nath, B., Melnick, E. R., & Tietbohl, C. K. (2023) · Implementation Science Communications · doi:10.1186/s43058-023-00421-7 · Cited by 8
Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals
Pham, S., Haigh, A., & Barrett, E. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000833 · Cited by 8
Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
Anderson, K. E., Saloner, B. K., Eckstein, J., Chaisson, C. E., Scholle, S. H., Niles, L. L., Dy, S. M., & Alexander, G. C. (2021) · Medical Care · doi:10.1097/mlr.0000000000001530 · Cited by 8
Peck, K. R., Ochalek, T. A., Streck, J. M., Badger, G. J., & Sigmon, S. C. (2021) · Pain Medicine · doi:10.1093/pm/pnab058 · Cited by 7
Harless, C., Hughes, P. M., Wilson, C. G., Carpenter, D. M., & Ostrach, B. M. M. (2022) · Southern Medical Journal · doi:10.14423/smj.0000000000001433 · Cited by 7
CareConnect: Adapting a Virtual Urgent Care Model to Provide Buprenorphine Transitional Care
Lowenstein, M., O’Donnell, N., Barnes, J., Gallagher, K., Gehri, G., Pomeroy, J. K., Aronowitz, S. V., Chaiyachati, K. H., Cubbage, E., French, R., et al. (2022) · NEJM Catalyst · doi:10.1056/cat.22.0274 · Cited by 7
Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use
Garcia, G. P., Dehghanpoor, R., Stringfellow, E. J., Gupta, M., Rochelle, J., Mason, E. M., Pujol, T. A., & Jalali, M. S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19106281 · Cited by 6
Martin, C. E., Scialli, A. C., & Terplan, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00003-6 · Cited by 6
A Novel Maintenance Therapeutic for Opioid Use Disorder
Youngblood, B. D., Li, K. D., Gehlert, D. R., Medina, J. C., & Schwartz, N. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000214 · Cited by 6
Paul, N., Kennedy, A. J., Taubenberger, S. P., Chang, J. C., & Hacker, K. A. (2022) · Substance Abuse · doi:10.1080/08897077.2021.2007518 · Cited by 6
Winograd, R., Coffey, B., Nance, M., & Carpenter, R. W. (2023) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2023.100514 · Cited by 6
Commentary on Burns et al: MOUD saves lives, especially after 60 days, and the longer the better
Williams, A. R. (2022) · Addiction · doi:10.1111/add.16043 · Cited by 6
Youngblood, B. D., Medina, J. C., Gehlert, D. R., & Schwartz, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1170541 · Cited by 5
Drive and Instinct—How They Produce Relatedness and Addiction
Ringwood, T., Cox, L., Felldin, B., Kirsch, M., & Johnson, B. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.657944 · Cited by 5
Opioid use disorder and concurrent benzodiazepine use: clinical risks and management strategies
Fakhri, A., Ritvo, A. D., Casarella, J., & Tang, Y. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2593244 · Cited by 4
Hagan, S. L., Achtmeyer, C. E., Hood, C., Hawkins, E. J., & Williams, E. C. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00280-4 · Cited by 4
Time to Change the Way We Approach Opioid Use Disorder: A Challenge to the Status Quo
Hawk, K. F., & D’Onofrio, G. (2018) · Annals of Internal Medicine · doi:10.7326/m18-2722 · Cited by 4
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study
Lowenstein, M., Davis, M. H., Aronowitz, S. V., Seeburger, E. F., & Grande, D. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112586 · Cited by 3
Heshmatipour, M., Duvernay, T. M., Hite, D. Z., Versi, E., Hite, M. P., Reeser, D., Prikhodko, V., Nelson, A. M., Julian, B., & Greenberg, M. L. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00554-1 · Cited by 3
Schottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2021) · Addiction · doi:10.1111/add.15399 · Cited by 3
Lépine, B., Debin, M., Dassieu, L., Gimenez, L., Palmaro, A., Ponté, C., Swital, M., Lapeyre‐Mestre, M., Blanchon, T., & Dupouy, J. (2024) · Therapies · doi:10.1016/j.therap.2024.04.002 · Cited by 3
Attitudinal barriers to buprenorphine prescription and former waiver training
Gannon, M. P., Tello, M. A., Wakeman, S. E., Charles, J.-P., Lipsitz, S. R., & Samal, L. (2024) · Journal of Opioid Management · doi:10.5055/jom.0827 · Cited by 2
Framework for opioid use disorder screening and diagnosis in carceral settings
Jack, H. E., Smith, C. L., Brinkley‐Rubinstein, L., & Berk, J. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104627 · Cited by 2
Martins, S., Huang, Y., Fan, W., Segura, L. E., Bruzelius, E., Marziali, M. E., Khan, A., & Philbin, M. M. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113158 · Cited by 2
Metadata
- Authors
- Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- University of Massachusetts Amherst (US)
- CleanSlate Research and Education Foundation, Florence, Massachusetts (A.W.)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-11-06
- Volume
- 169
- Issue
- 9
- Pages
- 628-635
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2898142040
- Cited by
- 130
- References
- 60
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 11 · 2023: 10 · 2022: 26 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 1
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, opioid use disorder, opioid substitution therapy, relapse, drug testing, polydrug use, treatment duration, evidence-based practice
- MeSH terms
- Benzodiazepines, Buprenorphine, Central Nervous System Agents, Counseling, Drug Therapy, Combination, Humans, Narcotic Antagonists, Opioid-Related Disorders, Recurrence, Substance Abuse Detection, Practice Guidelines as Topic, Patient-Centered Care, Evidence-Based Medicine, Opiate Substitution Treatment, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.